JAN 05, 2017 1:37 PM PST

Study: Chemo Brain Persists for Months After Treatment

WRITTEN BY: Xuan Pham

Chemotherapy is an aggressive attack on the cancer, and on the body. For some women treated with chemo for breast cancer, the effects of chemo seem to reach as far as the brain. The effect, dubbed “chemo brain,” is sparsely known but not deemed as a pervasive side effect of chemotherapy. But now, a new study sheds light on when chemo brain happens and the big impact this effect actually has on the lives of breast cancer patients.

Going through chemotherapy takes a toll on the body and the mind. But for years, doctors and patients focused more on the drugs’ effects on the body. Lapses in mental acuity and memory blurs after chemotherapy were perceived as anecdotal evidence of chemo’s effects in the brain. But it was only recently that researchers really took notice of these reports and linked chemo brain as a side effect of cancer treatment.

But just how pervasive this side effect really is was unknown. To understand this problem, researchers from the University of Rochester Medical Center in New York collected data from 581 breast cancer patients and 364 healthy women. The large sample size makes this one of the largest studies to date to investigate chemo brain.

Led by Michelle Janelsins, the team assessed the women’s cognitive status before, during, and after chemotherapy period. Of note, typical reports of chemo brain include mental fogginess, the inability to concentrate, and general difficulties with cognitive tasks that didn't use to be problematic.

To assess the women’s cognitive changes, the team used the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog), a well-known questionnaire that takes into account the patient’s perspective as well as the perspective of others around them.

The findings confirm that chemo brain is indeed quite real. A whopping 45.2 percent of breast cancer showed a decrease in FACT-Cog scores, while only 10.4 percent of healthy women reported any decline. More surprising, the effects seemed to persist even as long as 6 months after the treatment ended. At 6 months post-chemo, 18.4 percent of women with breast cancer still reported “clinically meaningful perceived decline” as compared to only 11.5 percent of control participants.

"Our study, from one of the largest nationwide studies to date, shows that cancer-related cognitive problems are a substantial and pervasive issue for many women with breast cancer,” said Janelsins.

Factors that exacerbate cognitive decline after chemo seem to include symptoms of anxiety and depression before chemotherapy. In addition, cognitive decline seemed to also be correlated with age and race.

“We are currently assessing these data in the context of objective cognitive measures and to understand the role of possible biologic mechanisms that may confer risk to cognitive problems in patients,” said Janelsins. Future studies may also point out if the link between chemotherapy and cognitive decline also includes male cancer patients.

Additional source: University of Rochester Medical Center press release, MNT

About the Author
I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUL 28, 2022
Clinical & Molecular DX
Pancreatic Cancer is Difficult to Detect in its Curable Early Stages: AI Could Soon Change This
JUL 28, 2022
Pancreatic Cancer is Difficult to Detect in its Curable Early Stages: AI Could Soon Change This
Pancreatic cancer typically does not cause symptoms until after it has spread to other organs. This makes it very diffic ...
SEP 14, 2022
Health & Medicine
Researchers Suggest Updating Alcohol Warning Labels
SEP 14, 2022
Researchers Suggest Updating Alcohol Warning Labels
Current warning labels that appear on alcohol products in the US are outdated, vague, and not helpful to people who want ...
OCT 13, 2022
Cancer
Gene Editing Beyond CRISPR-Cas9: Base Editors
OCT 13, 2022
Gene Editing Beyond CRISPR-Cas9: Base Editors
Point mutations change one or very few nucleotides in DNA, but they cause an estimated 30,000 genetic diseases in humans ...
OCT 06, 2022
Chemistry & Physics
2022 Nobel Prize in Chemistry
OCT 06, 2022
2022 Nobel Prize in Chemistry
It’s that time of year again! Three scientists, Carolyn R. Bertozzi, Morten Meldal, and K. Barry Sharpless, were a ...
OCT 10, 2022
Cancer
Experimental Drug Can Create Targets for Cancer-Killing Drugs
OCT 10, 2022
Experimental Drug Can Create Targets for Cancer-Killing Drugs
Immunotherapies continue to expand the cancer treatment landscape, providing new and exciting approaches to treat tumors ...
OCT 17, 2022
Cancer
The Value of Colonoscopy Screening
OCT 17, 2022
The Value of Colonoscopy Screening
Colorectal cancer (CRC) remains the third most common type of cancer diagnosed in men and women in the United States.&nb ...
Loading Comments...